The comparison used in the model also omitted newer classes of drugs available for the management of T2DM (including sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, and glucagon-like peptide 1 receptor agonists), which have been shown to provide benefits (35). Here, GLP1R is linked to type 2 diabetes mellitus.